PC-3 A reappraisal of CTLA-4 checkpoint blockade hypothesis in cancer immunotherapy
نویسندگان
چکیده
منابع مشابه
CTLA-4 checkpoint blockade in breast cancer, a case in point report
A patient concomitantly affected by breast cancer and melanoma is presented in order to contribute to the ongoing debate on breast cancer immunotherapy [1,2]. In 1996 the patient was operated on for left early breast cancer and treated with adjuvant radiotherapy and 5 years Tamoxifen. In 2009 biochemical progression and bone metastases appeared so Letrozole hormonal therapy was carried out, ens...
متن کاملCTLA-4 Antibodies in Cancer Immunotherapy
Activating human immune system to battle cancer has been a focus of cancer immunotherapy research from quite some time. After decades of disappointment, the tide has finally changed with some recent successes in clinical trials. The first such approach with clinical success is cytotoxic T lymphocyte antigen-4 (CTLA4) antibody therapy which aims to relieve the immune suppressive effects of CTLA-...
متن کاملCombination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
We have previously shown that antibodies to CTLA-4, an inhibitory receptor on T cells, can be effective at inducing regression of transplantable murine tumors. In this study, we demonstrate that an effective immune response against primary prostate tumors in transgenic (TRAMP) mice can be elicited using a strategy that combines CTLA-4 blockade and an irradiated tumor cell vaccine. Treatment of ...
متن کاملCombination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this study, we examined the effectiveness of 4-1BBL-expressing tumor cell vaccine in combination with C...
متن کاملEngagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAIDS Journal of Acquired Immune Deficiency Syndromes
سال: 2019
ISSN: 1525-4135
DOI: 10.1097/01.qai.0000558006.23515.a0